Xofigo FDA Approval History
FDA Approved: Yes (First approved May 15, 2013)
Brand name: Xofigo
Generic name: radium Ra 223 dichloride
Dosage form: Injection
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Prostate Cancer
Xofigo (radium 223 dichloride) is an alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer.
Development Timeline for Xofigo
|May 15, 2013||FDA Approves Xofigo for Advanced Prostate Cancer|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.